Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MARK3 | P27448 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14745520 | 0.81 | CYP19A1 (0.44) | CYP19A1CDK5CDK5R1AKT1FFAR1 | |
| SCHEMBL15058859 | 0.72 | CYP19A1 (0.81) | CYP19A1CDK5CDK5R1AKT1GSK3A | |
| SCHEMBL16441015 | 0.71 | CA2 (0.41) | GPR84 | |
| SCHEMBL693721 | 0.70 | CYP19A1 (0.61) | CYP19A1CDK5CDK5R1AKT1FFAR1 | |
| SCHEMBL16382899 | 0.70 | CYP19A1 (0.63) | CYP19A1CDK5CDK5R1AKT1GSK3A | |
| SCHEMBL693207 | 0.69 | CYP19A1 (0.52) | CYP19A1CDK5CDK5R1AKT1HDAC6 | |
| SCHEMBL16428431 | 0.69 | PGR (0.39) | GPR84 | |
| SCHEMBL16441013 | 0.69 | CA2 (0.41) | FFAR1 | |
| SCHEMBL14745185 | 0.68 | PPARG (0.46) | CYP19A1FFAR1 | |
| SCHEMBL14744717 | 0.68 | XDH (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | CYP19A1 4758/4885CDK5 4513/4885CDK5R1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.